{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:13:41Z","timestamp":1758039221562,"version":"3.44.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011772","name":"Novartis Farmac\u00e9utica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ad.2023.04.013","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T10:39:45Z","timestamp":1681555185000},"page":"T392-T401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["[Translated article] Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts"],"prefix":"10.1016","volume":"114","author":[{"given":"J.M.","family":"Carrascosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Vilarrasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Belinch\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Herranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Guimer\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Olveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2023.04.013_bib0475","first-page":"e201903013","article-title":"Prevalence of ten immune-mediated inflammatory diseases (IMID) in Spain","volume":"93","author":"Puig","year":"2019","journal-title":"Rev Esp Salud Publica"},{"key":"10.1016\/j.ad.2023.04.013_bib0480","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0485","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/ijms17020217","article-title":"Relationship between non-alcoholic fatty liver disease and psoriasis: a novel Hepato-Dermal axis?","volume":"17","author":"Mantovani","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ad.2023.04.013_bib0490","first-page":"161","article-title":"Looking for a new name for non-alcoholic fatty liver disease in Spanish: esteatosis hep\u00e1tica metab\u00f3lica (EHmet)","volume":"113","author":"Romero-G\u00f3mez","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.ad.2023.04.013_bib0495","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.3390\/ijerph18105227","article-title":"Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors","volume":"18","author":"Juanola","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ad.2023.04.013_bib0500","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.metabol.2017.04.011","article-title":"Non-alcoholic fatty liver disease: a sign of systemic disease","volume":"72","author":"Reccia","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.ad.2023.04.013_bib0505","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cld.2015.10.002","article-title":"The metabolic syndrome and its influence on nonalcoholic steatohepatitis","volume":"20","author":"Kanwar","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.ad.2023.04.013_bib0510","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2023.04.013_bib0515","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/TP.0000000000002484","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation","volume":"103","author":"Younossi","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.ad.2023.04.013_bib0520","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.gastrohep.2017.12.003","article-title":"Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline","volume":"41","author":"Aller","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0525","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2023.04.013_bib0530","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0535","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1038\/550S102a","article-title":"Fourth, the progression of liver disease in NASH is not linear and can be manifested by periods of progression, regression and stability","volume":"550","author":"Drew","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ad.2023.04.013_bib0540","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ad.2023.04.013_bib0545","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1111\/ajd.13015","article-title":"Relationship between psoriasis and non-alcoholic fatty liver disease \u2013 updated systematic review and adjusted meta-analysis","volume":"60","author":"Phan","year":"2019","journal-title":"Aust J Dermatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0550","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2009.04.020","article-title":"Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Gisondi","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0555","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-0960.2012.00905.x","article-title":"The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India","volume":"53","author":"Madanagobalane","year":"2012","journal-title":"Aust J Dermatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0560","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/jdv.12847","article-title":"Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis","volume":"29","author":"Candia","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.04.013_bib0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-88043-8","article-title":"Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients","volume":"11","author":"Belinch\u00f3n-Romero","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ad.2023.04.013_bib0570","doi-asserted-by":"crossref","first-page":"314","DOI":"10.17235\/reed.2019.6263\/2019","article-title":"Psoriasis and fatty liver: a harmful synergy","volume":"111","author":"Olveira","year":"2019","journal-title":"Rev Esp Enfermedades Dig"},{"key":"10.1016\/j.ad.2023.04.013_bib0575","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/jdv.13456","article-title":"Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis","volume":"30","author":"Gisondi","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.04.013_bib0580","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2023.04.013_bib0585","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2340\/00015555-2161","article-title":"Increased prevalence of advanced liver fibrosis in patients with psoriasis: a cross-sectional analysis from the Rotterdam study","volume":"96","author":"Vandervoort","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.04.013_bib0590","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/bjd.16239","article-title":"Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?","volume":"179","author":"Prussick","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/3140983","article-title":"Liver illness and psoriatic patients","volume":"2018","author":"Fiore","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ad.2023.04.013_bib0600","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.gastrohep.2022.04.001","article-title":"Consenso sobre m\u00e9todos de detecci\u00f3n y derivaci\u00f3n de enfermedades hep\u00e1ticas prevalentes ocultas. Consenso AEEH","volume":"46","author":"Romero G\u00f3mez","year":"2022","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0605","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0048-7120(01)73220-3","article-title":"M\u00e9todos de consenso Uso adecuado de la evidencia en la toma de decisiones. \u00abM\u00e9todo RAND\/UCLA\u00bb","volume":"35","author":"Mart\u00ednez-Sahuquillo Amuedo","year":"2001","journal-title":"Rehabilitaci\u00f3n"},{"key":"10.1016\/j.ad.2023.04.013_bib0610","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7748\/nr.22.3.35.e1297","article-title":"Research methods for formal consensus development","volume":"22","author":"James","year":"2015","journal-title":"Nurse Res"},{"key":"10.1016\/j.ad.2023.04.013_bib0615","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ad.2021.10.003","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.04.013_bib0620","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ad.2022.01.024","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.04.013_bib0625","first-page":"209","article-title":"Valoraci\u00f3n bioqu\u00edmica en la enfermedad hep\u00e1tica grasa asociada a la disfunci\u00f3n metab\u00f3lica","volume":"2","author":"Guerra-Ruiz","year":"2021","journal-title":"Adv Lab Med"},{"key":"10.1016\/j.ad.2023.04.013_bib0630","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0635","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2023.04.013_bib0640","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.endinu.2021.08.001","article-title":"Utilidad pr\u00e1ctica de los \u00edndices no invasivos en la esteatosis hep\u00e1tica metab\u00f3lica","volume":"69","author":"Tafur S\u00e1nchez","year":"2022","journal-title":"Endocrinol Diabetes Nutr"},{"key":"10.1016\/j.ad.2023.04.013_bib0645","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","article-title":"Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis","volume":"24","author":"Leoni","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ad.2023.04.013_bib0650","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2023.04.013_bib0655","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.ad.2023.04.013_bib0660","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/apt.14219","article-title":"Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD","volume":"46","author":"Petta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ad.2023.04.013_bib0665","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0670","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ad.2023.04.013_bib0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2019.05.051","article-title":"Development and validation of hepamet fibrosis scoring system \u2013 a simple noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis","volume":"18","author":"Ampuero","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0680","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ad.2023.04.013_bib0685","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ad.2023.04.013_bib0690","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2023.04.013_bib0695","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-230X-12-2","article-title":"Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population","volume":"12","author":"Sumida","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ad.2023.04.013_bib0700","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.dld.2017.05.002","article-title":"AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease","volume":"49","author":"Peleg","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ad.2023.04.013_bib0705","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","article-title":"Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease","volume":"57","author":"Harrison","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.ad.2023.04.013_bib0710","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.21984","article-title":"Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers","volume":"47","author":"Guha","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2023.04.013_bib0715","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis","volume":"29","author":"Sandrin","year":"2003","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.ad.2023.04.013_bib0720","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.rx.2017.11.002","article-title":"Liver elastography: what it is, how it is done, and how it is interpreted","volume":"60","author":"Murad Guti\u00e9rrez","year":"2018","journal-title":"Radiologia"},{"key":"10.1016\/j.ad.2023.04.013_bib0725","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23312","article-title":"Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2023.04.013_bib0730","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0735","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3748\/wjg.v25.i2.163","article-title":"Current status, problems, and perspectives of non-alcoholic fatty liver disease research","volume":"25","author":"Tanaka","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ad.2023.04.013_bib0740","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2023.04.013_bib0745","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep4.1019","article-title":"Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies","volume":"1","author":"Akuta","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ad.2023.04.013_bib0750","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2023.04.013_bib0755","unstructured":"ClinicalTrials.gov. A clinical study to evaluate the efficacy and safety of aramchol in subjects with NASH (ARMOR). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04104321 [accessed 1.7.22]."},{"key":"10.1016\/j.ad.2023.04.013_bib0760","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","article-title":"GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ad.2023.04.013_bib0765","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2023.04.013_bib0770","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ad.2023.04.013_bib0775","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ad.2023.04.013_bib0780","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/liv.12570","article-title":"The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis","volume":"35","author":"Barreyro","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.ad.2023.04.013_bib0785","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrgastro.2017.42","article-title":"NASH: novel therapeutic strategies targeting ASK1 in NASH","volume":"14","author":"Schuster","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0790","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2023.04.013_bib0795","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ad.2023.04.013_bib0800","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0168-8278(18)30425-2","article-title":"JKB-121 in patients with nonalcoholic steatohepatitis: a phase 2 double blind randomized placebo control study","volume":"68","author":"Diehl","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0805","unstructured":"ClinicalTrials.gov. JUNIPER: a phase 2 study to evaluate the safety, biological activity, and PK of ND-L02-s0201 in subjects with IPF. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03538301 [cited 2022, Jul 1]."},{"key":"10.1016\/j.ad.2023.04.013_bib0810","first-page":"46","article-title":"Systemic psoriasis therapies and comorbid disease in patients with psoriasis: a review of potential risks and benefits","volume":"12","author":"Mikhaylov","year":"2019","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0815","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bjd.12941","article-title":"Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies","volume":"171","author":"Maybury","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0820","unstructured":"NICE. Psoriasis: assessment and management (CG153). Clinical Guideline 84, no pagination, 2015."},{"key":"10.1016\/j.ad.2023.04.013_bib0825","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.amjms.2017.03.014","article-title":"Methotrexate hepatotoxicity and the impact of nonalcoholic fatty liver disease","volume":"354","author":"Shetty","year":"2017","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ad.2023.04.013_bib0830","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/09546634.2020.1801977","article-title":"Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study","volume":"33","author":"Rivera","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2023.04.013_bib0835","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha T\u00e9cnica de Metotrexato."},{"key":"10.1016\/j.ad.2023.04.013_bib0840","unstructured":"Ficha t\u00e9cnica de Acitretina. Agencia Europea de Medicamentos, 2020."},{"key":"10.1016\/j.ad.2023.04.013_bib0845","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tox.2013.01.020","article-title":"Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition: potential mechanisms of hepatotoxicity","volume":"306","author":"Silva","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.ad.2023.04.013_bib0850","unstructured":"Ficha t\u00e9cnica de Humira. Agencia Europea de Medicamentos, 2009."},{"key":"10.1016\/j.ad.2023.04.013_bib0855","unstructured":"Ficha t\u00e9cnica de Cimzia. Agencia Europea de Medicamentos, 2019."},{"key":"10.1016\/j.ad.2023.04.013_bib0860","unstructured":"Ficha t\u00e9cnica de Remicade. Agencia Europea de Medicamentos, 2014."},{"key":"10.1016\/j.ad.2023.04.013_bib0865","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha T\u00e9cnica de Ustekinumab, Stelara\u00ae, 2013."},{"journal-title":"Agencia Eur Med","first-page":"1","year":"2019","key":"10.1016\/j.ad.2023.04.013_bib0870"},{"key":"10.1016\/j.ad.2023.04.013_bib0875","unstructured":"Ficha t\u00e9cnica de Skyrizi. Agencia Europea de Medicamentos, 2014."},{"key":"10.1016\/j.ad.2023.04.013_bib0880","unstructured":"Ficha t\u00e9cnica de Tremfya. Agencia Europea de Medicamentos, 2009."},{"key":"10.1016\/j.ad.2023.04.013_bib0885","unstructured":"Ficha t\u00e9cnica de Cosentyx. Agencia Europea de Medicamentos, 2019."},{"key":"10.1016\/j.ad.2023.04.013_bib0890","unstructured":"Ficha t\u00e9cnica de Kyntheum. Agencia Europea de Medicamentos, 2014."},{"key":"10.1016\/j.ad.2023.04.013_bib0895","doi-asserted-by":"crossref","unstructured":"Ficha t\u00e9cnica de Taltz. Agencia Europea de Medicamentos, 2019. doi:10.2307\/j.ctvdf0dxq.12.","DOI":"10.2307\/j.ctvdf0dxq.12"},{"key":"10.1016\/j.ad.2023.04.013_bib0900","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2016.05.020","article-title":"Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma","volume":"30","author":"Gomes","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ad.2023.04.013_bib0905","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha T\u00e9cnica de Apremilast."},{"key":"10.1016\/j.ad.2023.04.013_bib0910","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ficha T\u00e9cnica Ciclosporina, 2020."},{"key":"10.1016\/j.ad.2023.04.013_bib0915","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0920","first-page":"1454","article-title":"Drug use and toxicity in psoriatic disease: focus on methotrexate","volume":"35","author":"Taylor","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0925","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ad.2019.07.002","article-title":"Validaci\u00f3n del m\u00e9todo de cuantificaci\u00f3n del \u00e1rea corporal afectada por la psoriasis mediante l\u00e1piz \u00f3ptico","volume":"111","author":"Reolid","year":"2020","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.04.013_bib0930","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1365-4632.2008.03753.x","article-title":"A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis","author":"Henseler","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2023.04.013_bib0935","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.det.2014.09.005","article-title":"Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice","volume":"33","author":"Chalmers","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.ad.2023.04.013_bib0940","unstructured":"Adaptaci\u00f3n transcultural al espa\u00f1ol del cuestionario Dermatology Life Quality Index (DLQI): El \u00cdndice de Calidad de Vida en Dermatolog\u00eda. Actas Dermo-Sifiliogr. Available from: https:\/\/www.actasdermo.org\/es-adaptacion-transcultural-al-espanol-del-articulo-13003408 [cited 2022, Jul 1]."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023002922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023002922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:15:12Z","timestamp":1757553312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731023002922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0001731023002922"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2023.04.013","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.01.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}